Solriamfetol hydrochloride is a Small Molecule owned by SK Biopharmaceuticals, and is involved in 21 clinical trials, of which 16 were completed, 4 are ongoing, and 1 is planned.

Solriamfetol has dual reuptake activity at dopamine and norepinephrine transporters. Moreover, the wake-promoting effects of solriamfetol are likely due to activity at dopamine (DA) and norepinephrine (NE) transporters rather than other neurotransmitter systems, such as histamine or orexin. The mechanism of action of solriamfetol includes low potency dopamine (DA) and norepinephrine (NE) reuptake inhibition via dopamine transporter (DAT) and norepinephrine transporter (NET), respectively.

The revenue for Solriamfetol hydrochloride is expected to reach a total of $3.2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Solriamfetol hydrochloride NPV Report.

Solriamfetol hydrochloride is originated and owned by SK Biopharmaceuticals. Axsome Therapeutics and Jazz Pharmaceuticals are the other companies associated in development or marketing of Solriamfetol hydrochloride.

Solriamfetol hydrochloride Overview

Solriamfetol hydrochloride (Sunosi) was a phenylalanine derivative, acts as an wake-promoting agent. It is formulated as film coated tablets for oral route of administration. Sunosi is indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA), and to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive  sleep  apnoea (OSA)  whose EDS has not been satisfactorily treated by primary OSA therapy, such as continuous positive airway pressure (CPAP).

Solriamfetol hydrochloride (SKL-N05/JZP-110/ADX-N05) is under development for the treatment of pediatric subjects with narcolepsy, excessive sleep in idiopathic Parkinson’s disease and attention deficit hyperactivity disorder (ADHD). It is administered orally. The drug candidate is an optically pure phenylalanine derivative. The adrenergic agent was also under development for the treatment of drug addiction and major depressive disorder.

Axsome Therapeutics Overview

Axsome Therapeutics (Axsome) is a biopharmaceutical company that develops and commercializes therapies for the treatment of central nervous system (CNS) disorders. The company’s pipeline product portfolio comprises AXS-05, for treatment of resistant depression, smoking cessation and agitation in Alzheimer’s disease, AXS-07, for treatment of migraine, AXS-12, for symptoms of narcolepsy, and AXS-14, for treatment of fibromyalgia. The company supplies its products through internal sales, distributors, and an internal marketing group in the US and outside the US. Axsome is headquartered in New York, the US.

The operating loss of the company was US$124.7 million in FY2021, compared to an operating loss of US$100.4 million in FY2020. The net loss of the company was US$130.4 million in FY2021, compared to a net loss of US$102.9 million in FY2020. The company reported revenues of US$16.9 million for the third quarter ended September 2022, an increase of 91% over the previous quarter.

Quick View – Solriamfetol hydrochloride

Report Segments
  • Innovator (NME)
Drug Name
  • Solriamfetol hydrochloride
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Respiratory
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.